• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by National Vision Holdings Inc.

    6/27/24 4:16:12 PM ET
    $EYE
    Ophthalmic Goods
    Health Care
    Get the next $EYE alert in real time by email
    S-8 1 tm2418218d1_s8.htm FORM S-8

     

     

    As filed with the Securities and Exchange Commission on June 27, 2024

    File No. 333-              

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

     

     

     

    NATIONAL VISION HOLDINGS, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   46-4841717
    (State or other jurisdiction of incorporation or
    organization)
      (I.R.S. Employer Identification No.)
         

    2435 Commerce Ave, Building 2200

    Duluth, Georgia

    (Address of Principal Executive Offices)

     

    30096

    (Zip Code)

     

    National Vision Holdings, Inc.

    Amended and Restated 2017 Omnibus Incentive Plan

    (Full title of the plan)

     

    Jared Brandman

    Senior Vice President, General Counsel and Secretary

    National Vision Holdings, Inc.

    2435 Commerce Ave, Building 2200

    Duluth, Georgia 30096

    (770) 822-3600

    (Name, address, and telephone number, including area code, of agent for service)

     

    With a copy to:

     

    Michael L. Stevens

    Alston & Bird LLP

    One Atlantic Center

    1201 W. Peachtree Street

    Atlanta, Georgia 30309

    (404) 881-7000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

     

    Large accelerated filer x  Accelerated filer ¨ 
    Non-accelerated filer ¨  Smaller reporting company ¨ 
        Emerging growth company ¨ 

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨ 

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    National Vision Holdings, Inc. (the “Company”) has filed this Registration Statement on Form S-8 (this “Registration Statement”) with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), to register (i) 5,600,000 shares of the Company’s common stock, $0.01 par value per share (“Common Stock”), that may be issued under the National Vision Holdings, Inc. Amended and Restated 2017 Omnibus Incentive Plan (the “Plan”); and (ii) such additional shares that may become issuable in accordance with the adjustment and anti-dilution provisions of the Plan. The Company previously registered, for issuance under the Plan, 4,000,000 shares on a Form S-8 filed on October 26, 2017 (File No. 333-221131).

     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    (a)       The documents constituting Part I of this Registration Statement will be sent or given to participants in the Plan as specified by Rule 428(b)(1) under the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this form, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    (b)       Upon written or oral request, the Company will provide, without charge, the documents incorporated by reference in Item 3 of Part II of this Registration Statement. The documents are incorporated by reference in the Section 10(a) prospectus. The Company will also provide, without charge, upon written or oral request, other documents required to be delivered to participants pursuant to Rule 428(b). Requests for the above mentioned information should be directed to the Company’s Secretary at telephone number (770) 822-3600 or the address on the cover of this Registration Statement.

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents, filed by the Company with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference and deemed to be a part hereof (excluding any portions of such documents that are deemed to be “furnished” but not “filed” for purposes of the Exchange Act):

     

    (a)The Company’s Annual Report on Form 10-K for the year ended December 30, 2023, filed with the Commission on February 27, 2024;

     

    (b)The Company’s Quarterly Report on Form 10-Q for the quarter ended March 30, 2024, filed with the Commission on May 8, 2024;

     

    (c)The Company’s Current Reports on Form 8-K, filed with the Commission on February 8, 2024 (Item 5.02 only); and

     

    (d)The description of the Common Stock contained in Company’s registration statement on Form 8-A (Registration No. 001-38257), filed with the Commission on October 24, 2017 pursuant to Section 12(b) of the Exchange Act, as amended by the description of the Common Stock contained in Exhibit 4.1 to our Annual Report on Form 10-K for the fiscal year ended January 1, 2022 (File No. 001-38257), filed with the Commission on February 28, 2022, and any amendment or report filed with the Commission for the purpose of updating such description.

     

    All reports and other documents filed (but not furnished) by the Company subsequent to the date of this Registration Statement pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all such securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     

     

    Other Information

     

    In the first quarter of 2024, the Company’s Management & Services Agreement with Walmart, along with various ancillary agreements, terminated. The Company is also winding down its Walmart associated contact lens business conducted by its subsidiary, Arlington Contacts Lens Service, Inc. The Company’s Walmart store operations, including its former Legacy reportable segment and certain other results previously included in its Corporate/Other and Reconciliations categories in its Financial Statements, met the criteria to be presented as discontinued operations as of March 30, 2024. Please see Notes 2, 3 and 12 to the Financial Statements of the Company’s Form 10-Q for the quarter ended March 31, 2024. The annual financial statements for the three years ended December 30, 2023 included in the Annual Report on Form 10-K for the year ended December 30, 2023, have not been updated for these discontinued operations.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    Section 102(b)(7) of the Delaware General Corporation Law, or the DGCL, allows a corporation to provide in its certificate of incorporation that a director of the corporation will not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except where the director breached the duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our amended and restated certificate of incorporation provides for this limitation of liability.

     

    Section 145 of the DGCL, or Section 145, provides, among other things, that a Delaware corporation may indemnify any person who was, is or is threatened to be made, party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or was an officer, director, employee or agent of such corporation or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided such person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the corporation’s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was unlawful.

     

    A Delaware corporation may indemnify any person who was or is or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the fact that such person is or was a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’ fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit, provided the person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation’s best interests, provided further that no indemnification is permitted without judicial approval if the officer, director, employee or agent is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify him or her against the expenses (including attorneys’ fees) which such officer or director has actually and reasonably incurred in connection with the defense.

     

    Section 145 further authorizes a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise, against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person’s status as such, whether or not the corporation would otherwise have the power to indemnify such person under Section 145.

     

     

     

      

    Our amended and restated bylaws provides that we must indemnify, and advance expenses to, our directors and officers to the full extent authorized by the DGCL. We have also entered into indemnification agreements with our directors, which agreements require us to indemnify these individuals to the fullest extent permitted under Delaware law against liabilities that may arise by reason of their service to us, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified.

     

    The indemnification rights set forth above shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under any statute, provision of our amended and restated certificate of incorporation, our amended and restated bylaws, agreement, vote of stockholders or disinterested directors or otherwise. Notwithstanding the foregoing, we shall not be obligated to indemnify a director or officer in respect of a proceeding (or part thereof) instituted by such director or officer, unless such proceeding (or part thereof) has been authorized by our Board of Directors pursuant to the applicable procedure outlined in the amended and restated bylaws.

     

    Section 174 of the DGCL provides, among other things, that a director, who willfully or negligently approves of an unlawful payment of dividends or an unlawful stock purchase or redemption, may be held jointly and severally liable for such actions at any time within 6 years after paying such unlawful dividend or after such unlawful stock purchase or redemption. A director who was either absent when the unlawful actions were approved or dissented at the time may avoid liability by causing his or her dissent to such actions to be entered in the books containing the minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent director receives notice of the unlawful acts.

     

    We maintain standard policies of insurance that provide coverage (1) to our directors and officers against loss rising from claims made by reason of breach of duty or other wrongful act and (2) to us with respect to indemnification payments that we may make to such directors and officers.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    Exhibit
    Number
      Description
       
    3.1   Third Amended and Restated Certificate of Incorporation of National Vision Holdings, Inc. (Incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K filed with the Commission on June 10, 2021).
       
    3.2   Fourth Amended and Restated Bylaws of National Vision Holdings, Inc. (Incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed with the Commission on December 12, 2023).
       
    5.1   Opinion of Alston & Bird LLP.
       
    23.1   Consent of Alston & Bird LLP (included in Exhibit 5.1).
       
    23.2   Consent of Deloitte & Touche LLP.
       
    24.1   Power of Attorney (included on the signature page of this Registration Statement).
       
    99.1   National Vision Holdings, Inc. Amended and Restated 2017 Omnibus Incentive Plan (Incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the Commission on June 13, 2024).
         
    107   Filing Fee Table.

     

     

     

     

    Item 9. Undertakings.

     

    (a)       The Company hereby undertakes:

     

    (1)       To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i)       To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii)      To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement; and

     

    (iii)     To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

     

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) immediately above do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Company pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

     

    (2)       That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3)       To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b)       The undersigned Company hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Company’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c)       Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Company of expenses incurred or paid by a director, officer or controlling person of the Company in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Company will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Duluth, state of Georgia, on this 27th day of June, 2024.

     

      NATIONAL VISION HOLDINGS, INC.
       
      By: /s/ L. Reade Fahs
        L. Reade Fahs
        Chief Executive Officer and Director

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jared Brandman, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, agent or his substitutes may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ L. Reade Fahs   Chief Executive Officer and Director (Principal Executive Officer)    June 27, 2024
    L. Reade Fahs      
             
    /s/ Melissa Rasmussen   Senior Vice President, Chief Financial Officer (Principal Financial and Accounting Officer)    June 27, 2024
    Melissa Rasmussen      
             
    /s/ D. Randolph Peeler   Director and Board Chair   June 27, 2024
    D. Randolph Peeler        
             
    /s/ Jose Armario   Director   June 27, 2024
    Jose Armario        
             
    /s/ Virginia A. Hepner   Director   June 27, 2024
    Virginia A. Hepner        
             
    /s/ Susan Somersille Johnson   Director   June 27, 2024
    Susan Somersille Johnson        
             
    /s/ Naomi Kelman   Director   June 27, 2024
    Naomi Kelman        
             
    /s/ Susan O’Farrell   Director   June 27, 2024
    Susan O’Farrell        
             
    /s/ Thomas V. Taylor, Jr.   Director   June 27, 2024
    Thomas V. Taylor, Jr.        

     

     

     

    Get the next $EYE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EYE

    DatePrice TargetRatingAnalyst
    12/10/2025$32.00Buy
    Guggenheim
    7/30/2025$36.00Buy
    Roth Capital
    7/8/2025$30.00Equal Weight → Overweight
    Barclays
    5/9/2025$21.00Neutral → Buy
    Citigroup
    5/7/2025Underperform → Buy
    BofA Securities
    10/17/2023$25.00 → $16.00Buy → Neutral
    Goldman
    7/27/2023$28.00 → $22.00Buy → Neutral
    Citigroup
    7/27/2023$30.00 → $21.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $EYE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Peeler D Randolph bought $264,200 worth of shares (25,000 units at $10.57) (SEC Form 4)

    4 - National Vision Holdings, Inc. (0001710155) (Issuer)

    8/14/24 4:27:52 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    Director Hepner Virginia A bought $10,365 worth of shares (1,000 units at $10.37), increasing direct ownership by 3% to 36,635 units (SEC Form 4)

    4 - National Vision Holdings, Inc. (0001710155) (Issuer)

    8/14/24 4:26:51 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    Fahs L Reade bought $299,200 worth of shares (20,000 units at $14.96), increasing direct ownership by 3% to 633,097 units (SEC Form 4)

    4 - National Vision Holdings, Inc. (0001710155) (Issuer)

    5/14/24 8:01:46 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by National Vision Holdings Inc.

    SCHEDULE 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

    2/10/26 11:21:53 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - National Vision Holdings, Inc. (0001710155) (Filer)

    12/16/25 4:30:58 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    SEC Form SCHEDULE 13G filed by National Vision Holdings Inc.

    SCHEDULE 13G - National Vision Holdings, Inc. (0001710155) (Subject)

    11/14/25 9:56:01 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    National Vision Reaffirms Fiscal 2025 Outlook Ahead of Participation at the ICR Conference

    National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today reaffirmed its fiscal 2025 outlook ahead of its participation at the 2026 ICR Conference. The Company reaffirms its fiscal 2025 outlook for the 53 weeks ending January 3, 2026, as set forth below. New Stores: ~32 Adjusted Comparable Store Sales Growth(1)(2): 5.0% - 6.0% Net Revenue: $1.970 billion - $1.988 billion(3) Adjusted Operating Income(2)(3): $92 million - $98 million Adjusted Diluted EPS(2)(3)(4): $0.63 - $0.71 Depreciation and Amortization(5): $91 million - $93 million Interest(6): $17 million - $19 million Tax Rate(7): 28% Capital Expenditures: $80 million - $85 mill

    1/13/26 7:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision Announces Participation in the 2026 ICR Conference

    National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced that the Company is scheduled to present at the 2026 ICR Conference on Tuesday, January 13, 2026, at 9:00 a.m. Eastern Time. A live webcast of the presentation can be accessed in the "Investors" section of the Company's website at ir.nationalvision.com. The webcast will be archived and available on the website shortly after the event. About National Vision Holdings, Inc. National Vision Holdings, Inc. (NASDAQ:EYE) is one of the largest optical retail companies in the United States with over 1,200 stores in 38 states and Puerto Rico. With a mission of helping people by making quality eye ca

    1/6/26 4:05:00 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision Announces Participation in Morgan Stanley Global Consumer & Retail Conference

    National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced that the Company is scheduled to present at the Morgan Stanley Global Consumer & Retail Conference on Wednesday, December 3, 2025, at 11:45 a.m. Eastern Time. A live webcast of the presentation can be accessed in the "Investors" section of the Company's website at www.ir.nationalvision.com. The webcast will be archived and available on the website shortly after the event. About National Vision Holdings, Inc. National Vision Holdings, Inc. (NASDAQ:EYE) is one of the largest optical retail companies in the United States with over 1,200 stores in 38 states and Puerto Rico. With a mission of help

    11/26/25 8:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on National Vision with a new price target

    Guggenheim initiated coverage of National Vision with a rating of Buy and set a new price target of $32.00

    12/10/25 8:28:45 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    Roth Capital initiated coverage on National Vision with a new price target

    Roth Capital initiated coverage of National Vision with a rating of Buy and set a new price target of $36.00

    7/30/25 7:33:08 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision upgraded by Barclays with a new price target

    Barclays upgraded National Vision from Equal Weight to Overweight and set a new price target of $30.00

    7/8/25 8:23:14 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Manager Patel Priti V covered exercise/tax liability with 538 shares and converted options into 1,502 shares, increasing direct ownership by 7% to 13,869 units (SEC Form 4)

    4 - National Vision Holdings, Inc. (0001710155) (Issuer)

    10/6/25 4:44:22 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    Executive Chairman Fahs L Reade sold $301,278 worth of shares (12,600 units at $23.91), decreasing direct ownership by 2% to 532,195 units (SEC Form 4)

    4 - National Vision Holdings, Inc. (0001710155) (Issuer)

    9/17/25 4:11:52 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by Chief Technology Officer Cutler David G

    4 - National Vision Holdings, Inc. (0001710155) (Issuer)

    9/9/25 4:23:22 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    Leadership Updates

    Live Leadership Updates

    View All

    National Vision, Inc. Unveils Bold New Brand Identity as Part of Strategic Transformation

    Brand refresh underscores National Vision's continued business evolution and unwavering commitment to accessible, high-quality eye care and eyewear DULUTH, Ga., Aug. 5, 2025 /PRNewswire/ -- National Vision Holdings, Inc. (NASDAQ:EYE), one of the largest optical retail companies in the United States, unveiled its new corporate brand identity, a major milestone in National Vision's transformation journey. The refreshed branding strengthens National Vision's position as a modern, agile and purpose-driven organization committed to helping people see their best to live their best. Experience the full interactive Multichannel News Release here: https://www.multivu.com/national-vision-holdings/934

    8/5/25 8:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision Appoints Alex Wilkes as CEO

    Reade Fahs to Assume Executive Chairman Position Transition Effective August 1, 2025 National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced that its Board of Directors has appointed Alex Wilkes as the Company's next Chief Executive Officer, effective August 1, 2025, and he will join the Company's Board at that time. Mr. Wilkes succeeds Reade Fahs who will assume the role of Executive Chairman of the Board. Mr. Fahs will continue to work closely with Mr. Wilkes, ensuring a smooth transition. "National Vision has been on a journey of significant transformation for the past few years, and today I am pleased to announce the next chapter in that tran

    4/29/25 6:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision Appoints Jim McGrann and Michael Nicholson to Board of Directors

    Enters into Cooperation Agreement with Engine Capital National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced the appointment of two new independent directors, Jim McGrann and Michael Nicholson to its Board of Directors (the "Board"), effective March 17, 2025. Mr. McGrann will serve on the Board's Compensation Committee and Mr. Nicholson will serve on the Board's Audit Committee and Nominating and Corporate Governance Committee. With the addition of Messrs. McGrann and Nicholson, the Board will expand from 9 to 11 members. The Board has also formed an Advisory Committee that will help oversee National Vision's ongoing transformation initiatives with

    3/17/25 4:05:00 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

    SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

    11/14/24 12:33:08 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

    SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

    11/12/24 4:45:48 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

    SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

    11/4/24 1:18:26 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    Financials

    Live finance-specific insights

    View All

    National Vision Holdings, Inc. Reports Third Quarter 2025 Financial Results

    Transformation Initiatives Continue to Drive Strong Performance Raises Fiscal 2025 Outlook Third quarter 2025 highlights compared to third quarter 2024: Net revenue from continuing operations increased 7.9% to $487.3 million Comparable store sales growth of 6.8% and Adjusted Comparable Store Sales Growth of 7.7% represented the 11th consecutive quarter of positive growth Income from continuing operations of $3.4 million, Diluted EPS from continuing operations of $0.04, with Income (loss) from continuing operations margin improving to 0.7% from (1.9)% Adjusted Operating Income from continuing operations of $19.8 million, up 38.6%, with Adjusted Operating Margin improving to 4.1% fro

    11/5/25 6:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision Holdings, Inc. Announces Third Quarter 2025 Earnings Release and Conference Call

    National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") will report its third quarter 2025 financial results before the market opens on Wednesday, November 5, 2025, and will host a conference call at 8:30 a.m. Eastern Time. To pre-register for the conference call and obtain a dial-in number and passcode, please refer to the "Investors" section of the Company's website at https://ir.nationalvision.com. A live audio webcast of the conference call, together with related materials, will be available online in the "Investors" section of the Company's website. A replay of the audio webcast will be available shortly after the broadcast. About National Vision Holdings,

    10/22/25 8:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision Holdings, Inc. Reports Second Quarter 2025 Financial Results

    Accelerated Initiatives Drive Comparable Store Sales Growth and Improved Profitability Raises Fiscal 2025 Outlook Second quarter 2025 highlights compared to second quarter 2024: Net revenue from continuing operations increased 7.7% to $486.4 million Comparable store sales growth of 6.5% and Adjusted Comparable Store Sales Growth of 5.9% represented the 10th consecutive quarter of positive growth Income from continuing operations of $8.7 million, Diluted EPS from continuing operations of $0.11 Adjusted Operating Income from continuing operations of $23.8 million, up 69.1%, with Adjusted Operating Margin improving to 4.9% from 3.1% Adjusted Diluted EPS from continuing operati

    8/6/25 6:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care